Almost 16 million adults have COPD in the United States and about 3 in 4 people with this condition have at least one flare (exacerbation) a year, cites a review. But you don’t have to sit and wait ...

The main goals of chronic obstructive pulmonary disease (COPD) management include treatment of symptoms and prevention of exacerbations. Current guidelines recommend use of one or more long-acting ...

A discrete choice experiment found that patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) valued improvement in their daily symptoms more than improvement of exacerbations.

Please provide your email address to receive an email when new articles are posted on . This analysis focused on adults with moderate to severe COPD without an exacerbation during the ENHANCE trials.

Imaging and clinical characteristics reach high diagnostic efficacy when they are used to identify frequent acute exacerbations in patients with chronic obstructive pulmonary disease (COPD). A mix of ...

This study involved 307 patients with COPD enrolled in the London COPD cohort and included their contributing data from at least 1 year between November 1, 1995, and November 1, 2009. The patients and ...

telemedicine Researchers examined the risks for pneumonia and exacerbation of COPD after PPI treatment for GERD. The risk for symptom exacerbation reduced after PPI treatment for patients with GERD ...

COPD, or chronic obstructive pulmonary disease, is a leading cause of disability and death in the U.S., according to the American Lung Association. More than 12.5 million people have been diagnosed ...

Chronic obstructive pulmonary disease (COPD) isn’t just one condition. It’s a family of diseases such as emphysema and chronic bronchitis that interfere with your breathing. In chronic bronchitis, ...

Please provide your email address to receive an email when new articles are posted on . Minimum pitch in the morning was significantly higher at exacerbation onset and peak vs. baseline. In the ...

WASHINGTON -- Among chronic obstructive pulmonary disease (COPD) patients with type 2 inflammation at high risk for exacerbations despite being on standard triple therapy, adding dupilumab (Dupixent) ...

GlaxoSmithKline’s (GSK) Nucala (mepolizumab) has been approved by the MHRA to treat adults with uncontrolled chronic obstructive pulmonary disease (COPD).